As we mentioned before, recent evidence indicates that DAAs induce upregulation of VEGF expression in the liver, which promotes HCC occurrence/recurrence in susceptible patients, particularly those with advanced fibrosis or cirrhosis, who already exhibit abnormal activation of neo-angiogenic pathways like angiopoietin-2 in their liver tissue [67]. Here, VEGFA is linked to fibrosis.